Pfizer Inc. (PFE)
After hours:
| Previous Close | 50.65 |
| Open | 51.26 |
| Bid | 53.87 x 1800 |
| Ask | 53.98 x 4000 |
| Day's Range | 51.13 - 52.70 |
| 52 Week Range | 38.48 - 61.71 |
| Volume | |
| Avg. Volume | 27,271,677 |
| Market Cap | 302.59B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | 15.40 |
| EPS (TTM) | 3.50 |
| Earnings Date | May 02, 2022 - May 06, 2022 |
| Forward Dividend & Yield | 1.60 (3.21%) |
| Ex-Dividend Date | May 12, 2022 |
| 1y Target Est | 59.33 |
- Zacks
Pfizer (PFE) Gets Fast Track Designation for NASH Therapy
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
- Zacks
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
- Business Wire
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
NEW YORK, May 26, 2022--Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis: ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi). Fast Track is a process designed to facilitate the development and ex
